Stock Market Reviews

ZBIO (Zenas BioPharma, Inc.) News

Get the latest news, insights, and market updates on ZBIO (Zenas BioPharma, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  WALTHAM, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on December 15, 2025 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase 300,000 shares of t
  Dec 19, 2025 - $ZBIO
• Zenas BioPharma (ZBIO): Reassessing Valuation After Orelabrutinib’s Phase 2b Lupus Success and China Phase 3 Green Light
  Zenas BioPharma (ZBIO) is back in focus after partner InnoCare reported that orelabrutinib hit its primary endpoint in a Phase 2b lupus trial, and China has cleared a Phase 3 registrational study. See our latest analysis for Zenas BioPharma. The latest orelabrutinib update comes after a huge run, with Zenas BioPharma’s share price return up sharply year to date but cooling recently. This suggests investors are reassessing risk after a rapid re‑rating. If this kind of clinical momentum has...
  Dec 16, 2025 - $ZBIO
• Zenas BioPharma Says Partner InnoCare's Phase 2b Orelabrutinib Study in Systemic Lupus Erythematosus Meets Primary Endpoint
  Zenas BioPharma (ZBIO) said Monday that its partner InnoCare Pharma's phase 2b study evaluating orel
  Dec 15, 2025 - $ZBIO
• Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
  - Orelabrutinib is the first BTK inhibitor to demonstrate significant clinical activity in a Phase 2 clinical trial for SLE - - Zenas acquired the exclusive right to develop, manufacture and commercialize orelabrutinib in the field of Multiple Sclerosis globally, and non-oncology fields in all territories outside Greater China and Southeast Asia, in October 2025 license agreement with InnoCare – WALTHAM, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” o
  Dec 15, 2025 - $ZBIO
• Huge Insider Buying in MGM and Salesforce
  As the year winds down, insiders make huge buys in MGM Resorts and Salesforce. However, those were not the only notable instances of insider buying seen recently.
  Dec 12, 2025 - $ZBIO
• Meridian Small Cap Growth Fund Trimmed Zenas BioPharma (ZBIO) Following Share Price Appreciation
  Meridian Funds, managed by ArrowMark Partners, released its third-quarter 2025 investor letter for the “Meridian Small Cap Growth Fund.” A copy of the letter can be downloaded here. Driven by continued gains in technology and falling bond yields, equities reached record highs in the quarter. U.S. small caps outperformed in the quarter, gaining 12.4%, while […]
  Dec 3, 2025 - $ZBIO
• Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
  - Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 - - Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS) - - Secured development and commercialization rights for three autoimmune product candidates, including orelabrutinib, a BTK Inhibitor in Phase 3 development for progressive forms of Multiple Sclerosis (MS) - - Entered into obexelimab funding agr
  Nov 12, 2025 - $ZBIO
• Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
  WALTHAM, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced management’s presentations at the following investor conferences: Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025, at 11:00 a.m. GMT8th Annual Ev
  Nov 11, 2025 - $ZBIO
• The Bull Case For Royalty Pharma (RPRX) Could Change Following $2 Billion Debt Raise and New Royalty Deals
  Recently, Royalty Pharma raised US$2 billion through senior unsecured notes and acquired royalty interests in Amgen's cancer drug IMDELLTRA, while also committing up to US$300 million for a royalty on Zenas BioPharma’s autoimmune drug candidate tied to clinical milestones. These moves reflect Royalty Pharma's focus on building a diversified, lower-risk revenue portfolio by investing in high-value, late-stage, and marketed drug assets. We'll explore how Royalty Pharma’s sizable funding...
  Nov 2, 2025 - $ZBIO
• How Royalty Pharma Prints Cash Without Biotech's Biggest Risks
  Royalty Pharma's recent deals for promising new therapies highlight its unique and successful strategy of funding blockbuster innovation for long-term growth.
  Oct 31, 2025 - $ZBIO